Overview

Pediatric acute myeloid leukemias are disease with poor prognosis (overall survival of 60-75%) and high relapse rate of 35-45% require further understanding of the underlying biological mechanisms.

The main objective of this study is to establish a biological collection to evaluate the genomic profiling of leukemic cells from primary blasts at diagnosis and/or relapse to improve identification of the main genetic hits involved in resistance and could predict a high risk of relapse. Other objectives include the study of bone marrow mesenchymal stem cells and ex vivo drug testing.

Eligibility

Inclusion Criteria:

• 0-25 years old
• Newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML) or
• Relapsed or refractory AML or
• Patients with genetic predisposition to develop AML or
• Patients without haematological malignancy nor AML genetic predisposition syndrome who undergo bone marrow aspirate as part of standard of care
• Signed informed consent of parents for patients aged less than 18 years old or signed informed consent of the patient for patients aged 18 and over.

Exclusion Criteria:

• Refuse to participate
• Chronic myeloid leukemia (CML)
• Lack of health insurance (French social security)
• Under protection (tutelle, curatelle or sauvegarde de justice)
• Pregnancy or breastfeeding